SCHEMBL2212154

SCHEMBL2212154

CC(=O)c1ccc(S(=O)(=O)CCCC(=O)O)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.60
KDM4E B2RXH2 1/20 0.54
HTT P42858 3/20 0.51
NPSR1 Q6W5P4 1/20 0.51
ALDH1A1 P00352 5/20 0.47
CYP3A4 P08684 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
THRA P10827 1/20 0.46
THRB P10828 1/20 0.46
CYSLTR2 Q9NS75 1/20 0.46
CYSLTR1 Q9Y271 1/20 0.46
KMT2A Q03164 5/20 0.45
MEN1 O00255 1/20 0.45
LMNA P02545 1/20 0.45
GAA P10253 1/20 0.45
POLB P06746 1/20 0.44
MAPT P10636 1/20 0.44
CA12 O43570 1/20 0.44
CA9 Q16790 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6470799 0.90 KDM4E (0.66) HSD17B10KDM4EHTTNPSR1ALDH1A1
SCHEMBL8313367 0.83 CA2 (0.61) HSD17B10HTTALDH1A1CYP3A4CYP2C9
SCHEMBL19066564 0.83 ALDH1A1 (0.69) HSD17B10KDM4EHTTNPSR1ALDH1A1
SCHEMBL11727133 0.81 HDAC1 (0.61) HSD17B10KMT2ALMNAPOLBCA12
SCHEMBL5128861 0.80 HDAC1 (0.60) KDM4EHTTNPSR1ALDH1A1POLB
SCHEMBL10419192 0.79 MMP2 (0.59) ALDH1A1POLBCA12CA9HSD11B1
SCHEMBL20796169 0.79 ALDH1A1 (0.52) KDM4EHTTALDH1A1THRATHRB
Hydrochloric Acid SCHEMBL5120938 0.79 HDAC1 (0.58) KDM4EHTTNPSR1ALDH1A1POLB
SCHEMBL7077677 0.79 HTT (0.82) HTTNPSR1ALDH1A1KMT2AMEN1
SCHEMBL5189622 0.78 ALDH1A1 (0.67) KDM4EHTTNPSR1ALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1389616-B1 3,4-Dihalobenzylpiperidine derivatives and their medical use MITSUBISHI TANABE PHARMA CORP (JP) 2011-07-27 EP disclosed
US-7115635-B2 Benzylpiperidine compound MITSUBISHI PHARMA CORPORATION (JP) 2006-10-03 US disclosed
US-20040158071-A1 Chemokine inhibitors and stability in blood MITSUBISHI PHARMA CORPORATION (JP) 2004-08-12 US disclosed
EP-1389616-A1 NOVEL BENZYLPIPERIDINE COMPOUND Mitsubishi Pharma Corporation (JP) 2004-02-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040158071-A1 Chemokine inhibitors and stability in blood CCL2, CXCR1, CCR5 HSD17B10 2037/4885KDM4E 3615/4885HTT 4507/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.